For the prevention of meningococcal group B disease (also known as meningitis B)
Talk to your healthcare provider
about vaccinating with TRUMENBA
Because
they share
INDICATION
• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for
active immunization to prevent invasive disease caused by Neisseria meningitidis
group B
• Trumenba is approved based upon demonstrated immune response gainst four
group B strains representative of prevalent strains in the US. The effectiveness of
Trumenba against diverse group B strains has not been confirmed
IMPORTANT SAFETY INFORMATION
TRUMENBA is proven to help protect 10 through
25 year olds against uncommon, but potentially
deadly, meningitis B1,2
Please see full Important Safety Information on page 4 and click here
for full Prescribing Information.
• Trumenba should not be given to anyone with a history of a severe allergic reaction
after a previous dose of Trumenba
• Individuals with weakened immune systems may have a reduced immune response
BecauseTheyShare.com
®
Meningococcal Group B Vaccine
Info to know and share
Meningitis B, a form of invasive meningococcal
disease, is a bacterial infection that attacks
the brain and spinal cord3
here are 5 primary types of the bacteria that cause meningococcal disease:
T
A, C, Y, W, and B4
here have been vaccines approved to protect against A, C, Y, and W. Until
T
2014 in the US, there were no vaccines to protect against B4
hough not common, when it occurs, meningitis B, like other forms of
T
meningococcal disease, may potentially lead to5
• Death within 24 hours
• Loss of limbs
• Brain damage
• Scarring
• Hearing loss
Your child may be sharing more
than they think
In the US, meningitis B is responsible for approximately 30% of invasive
meningococcal disease cases (11 through 24 years of age)4
n average, 1 in 10 adolescents and young adults who develop
O
meningitis B will die from it6
arly symptoms of meningitis B may seem like the flu; you and your child
E
may not realize it’s something serious until it’s too late3
Did you know?
The bacteria that cause meningitis B spread
through typical adolescent behavior, like kissing;
sharing drinks, utensils, and cosmetics; and living
in close quarters.3
INDICATION
•T
rumenba is a vaccine indicated for individuals 10 through 25 years of age
for active immunization to prevent invasive disease caused by Neisseria
meningitidis group B
• Trumenba is approved based upon demonstrated immune response against
four group B strains representative of prevalent strains in the US. The
effectiveness of Trumenba against diverse group B strains has not
been confirmed
IMPORTANT SAFETY INFORMATION
• Individuals with weakened immune systems may have a reduced immune response
• The most common adverse reactions were pain at the injection site, fatigue,
headache, muscle pain, and chills
Please see full Important Safety Information on page 4 and click here for full
Prescribing Information.
2
Help protect your children, 10
through 25 years of age, against
meningitis B, with TRUMENBA
Approved by the FDA for the prevention of meningitis B
TRUMENBA is a meningitis B vaccine clinically studied in the
United States1
atients in TRUMENBA clinical trials were adolescents and
P
young adults1
How TRUMENBA works
nly TRUMENBA targets both subfamilies of factor H binding protein (fHBP),
O
a protein found in over 97% of disease-causing meningitis B bacteria1,7
This means TRUMENBA provides protection against meningitis B strains1
Talk to your healthcare
provider about vaccinating
your child against meningitis B,
with TRUMENBA
Use the following table to track your child’s dosing schedule
to ensure that he or she gets all 3 recommended doses
Dose 1
(now)
Got it!
Got it!
Dose 3
Got it!
(6 months after dose 1)
Please see full Important Safety Information on page 4 and click here for full
Prescribing Information.
3
•T
rumenba is a vaccine indicated for individuals 10 through 25 years
of age for active immunization to prevent invasive disease caused by
Neisseria meningitidis group B
•T
rumenba is approved based upon demonstrated immune response
against four group B strains representative of prevalent strains in the US.
The effectiveness of Trumenba against diverse group B strains has not
been confirmed
IMPORTANT SAFETY INFORMATION
Dose 2
(2 months after dose 1)
INDICATION
•D
ata are not available on the safety and effectiveness of using Trumenba
and other meningococcal group B vaccines interchangeably to complete
the vaccination series
Visit BecauseTheyShare.com
to learn more
Important safety info
about TRUMENBA
The safety data demonstrated that TRUMENBA was generally
well tolerated
he most commonly reported adverse reactions were pain at the injection site,
T
fatigue, headache, muscle pain, and chills1
INDICATION
•T
rumenba is a vaccine indicated for individuals 10 through 25 years of age for active
immunization to prevent invasive disease caused by Neisseria meningitidis group B
•T
rumenba is approved based upon demonstrated immune response against four group
B strains representative of prevalent strains in the US. The effectiveness of Trumenba
against diverse group B strains has not been confirmed
IMPORTANT SAFETY INFORMATION
• Trumenba should not be given to anyone with a history of a severe allergic reaction
after a previous dose of Trumenba
• Individuals with weakened immune systems may have a reduced immune response
• The most common adverse reactions were pain at the injection site, fatigue, headache,
muscle pain, and chills
• Data are not available on the safety and effectiveness of using Trumenba and other
meningococcal group B vaccines interchangeably to complete the vaccination series
• Tell your healthcare provider if you are pregnant, or plan to become pregnant
• Ask your healthcare provider about the risks and benefits of Trumenba. Only a
healthcare provider can decide if Trumenba is right for you or your child
Click here for full Prescribing Information.
4
TRUMENBA helps protect
10 through 25 year olds
against meningitis B1
Because they’ll
keep sharing
INDICATION
• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active
immunization to prevent invasive disease caused by Neisseria meningitidis group B
•T
rumenba is approved based upon demonstrated immune response against four group
B strains representative of prevalent strains in the US. The effectiveness of Trumenba
against diverse group B strains has not been confirmed
IMPORTANT SAFETY INFORMATION
• Trumenba should not be given to anyone with a history of a severe allergic reaction after
a previous dose of Trumenba
• Individuals with weakened immune systems may have a reduced immune response
You are encouraged to report negative side effects of vaccines to the US Food and Drug
Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
Visit www.vaers.hhs.gov or call 1-800-822-7967.
Please see full Important Safety Information on page 4 and click here for full Prescribing Information.
Call 1-844-TRUMENBA (878-6362), 9 am to 7
Monday through Friday, for more information.
VCD697400-01
© 2014 Pfizer Inc.
All rights reserved. November 2014
pm
ET,
Get serious about protection—
talk to your healthcare provider
about vaccinating your child
with TRUMENBA
For more information, visit
BecauseTheyShare.com
References: 1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; October 2014. 2. Poland, GA. Prevention of meningococcal disease: current
use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(suppl 2):S45-S53. 3. Centers for Disease Control and Prevention. Meningococcal
disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated April 1, 2014. Accessed October 16, 2014.
4. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR. 2013;62(RR-2):1-28. 5. Meningitis Research Foundation. Meningococcal meningitis and septicaemia: guidance notes: diagnosis and treatment in general
practice, 2014 edition. http://www.meningitis.org/assets/x/50631. Accessed September 19, 2014. 6. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria
meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.
7. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular
polysaccharide. Vaccine. 2009;27(25-26):3417-3421.
®
Meningococcal Group B Vaccine